Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial

European Journal of Cancer

Volumn 63, Issue , 2016, Pages 97-104

  Ignatiadis, Michail ^a   Rack, Brigitte ^b   Rothé, Francoise ^a   Riethdorf, Sabine ^c   Decraene, Charles ^d   Bonnefoi, Hervé ^e   Dittrich, Christian ^f   Messina, Carlo ^g   Beauvois, Melanie ^h   Trapp, Elisabeth ^b   Goulioti, Theodora ⁱ   Tryfonidis, Konstantinos ^h   Pantel, Klaus ^c   Repollet, Madeline ^j   Janni, Wolfgang ^k   Piccart, Martine ^a   Sotiriou, Christos ^a   Litiere, Saskia ^h   Pierga, Jean Yves ^d  

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d INSTITUT CURIE   (France)

^e INSTITUT BERGONIÉ   (France)

^f KAISER FRANZ JOSEF HOSPITAL   (Austria)

^g F HOFFMANN LA ROCHE LTD   (Switzerland)

^h EORTC DATA CENTER   (Belgium)

ⁱ Breast International Group   (Belgium)

^j JOHNSON AND JOHNSON   (United States)

^k UNIVERSITY HOSPITAL ULM   (Germany)

more..

Author keywords

Adjuvant treatment; Breast cancer; CTC

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; BREAST CANCER; CANCER PROGNOSIS; CANCER SCREENING; CIRCULATING TUMOR CELL; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; EARLY CANCER; FEMALE; HUMAN; LIQUID BIOPSY; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; REVIEW; TUMOR BIOPSY; VERY ELDERLY; BIOPSY; BREAST NEOPLASMS; MIDDLE AGED; PATHOLOGY; PILOT STUDY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; TUMOR EMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BIOPSY; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM, RESIDUAL; NEOPLASTIC CELLS, CIRCULATING; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TRASTUZUMAB;

EID: 84973569059     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.04.024     Document Type: Review

References (37)

1. M.G. von, M. Untch, J.U. Blohmer, and et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes J Clin Oncol 30 15 2012 May 20 1796 1804
2. A. Berruti, V. Amoroso, F. Gallo, and et al. Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies J Clin Oncol 32 34 2014 Dec 1 3883 3891
3. P. Cortazar, L. Zhang, M. Untch, and et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Lancet 384 9938 2014 Jul 12 164 172
4. S. Loibl, G. von Minckwitz, A. Schneeweiss, and et al. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer J Clin Oncol 32 29 2014 Oct 10 3212 3220
5. I.J. Majewski, P. Nuciforo, L. Mittempergher, and et al. PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer J Clin Oncol 33 12 2015 Apr,20 1334 1339 doi: 10.1200(12), JCO2014552158
6. K.L. Pogue-Geile, N. Song, J.H. Jeong, and et al. Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial J Clin Oncol 33 12 2015 Apr,20 1340 1347 doi: 10.1200(12), JCO2014562439
7. J. Baselga, I. Bradbury, H. Eidtmann, and et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Lancet 379 9816 2012 Feb 18 633 640
8. M.J. Piccart-Gebhart, P.A. Holmes, J. Baselga, and et al. First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T->L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC) J Clin Oncol 32 5s 2014 Suppl; abstr LBA4
9. M. Gerlinger, and C. Swanton How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine Br J Cancer 103 8 2010 Oct 12 1139 1143
10. L.R. Yates, and P.J. Campbell Evolution of the cancer genome Nat Rev Genet 13 11 2012 Nov 795 806
11. M.G. Krebs, R.L. Metcalf, L. Carter, G. Brady, F.H. Blackhall, and C. Dive Molecular analysis of circulating tumour cells-biology and biomarkers Nat Rev Clin Oncol 11 3 2014 Mar 129 144
12. M. Ignatiadis, M. Lee, and S.S. Jeffrey Circulating tumor cells and circulating tumor DNA: challenges and opportunities on the path to clinical utility Clin Cancer Res 21 21 2015 Nov 1 4786 4800
13. M. Ignatiadis, N. Xenidis, M. Perraki, and et al. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer J Clin Oncol 25 33 2007 Nov 20 5194 5202
14. N. Xenidis, M. Ignatiadis, S. Apostolaki, and et al. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer J Clin Oncol 27 13 2009 May 1 2177 2184
15. B. Rack, C. Schindlbeck, J. Juckstock, and et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients J Natl Cancer Inst 5 2014 May 15
16. F.C. Bidard, C. Mathiot, S. Delaloge, and et al. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer Ann Oncol 21 4 2010 Apr 729 733
17. A. Lucci, C.S. Hall, A.K. Lodhi, and et al. Circulating tumour cells in non-metastatic breast cancer: a prospective study Lancet Oncol 13 7 2012 Jul 688 695
18. B. Franken, M.R. Degroot, W.J. Mastboom, and et al. Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer Breast Cancer Res 14 5 2012 Oct 22 R133
19. W. Janni, B. Rack, L.W.M.M. Terstappen, and et al. A pooled analysis of the prognostic relevance of circulating tumor cells in early breast cancer Cancer Res 73 24 Supplement 2013 PD6 6
20. M. Ignatiadis, S. Riethdorf, F.C. Bidard, and et al. International study on inter-reader variability for circulating tumor cells in breast cancer Breast Cancer Res 2 2014 Apr 23
21. S. Paik, C. Kim, and N. Wolmark HER2 status and benefit from adjuvant trastuzumab in breast cancer N Engl J Med 358 13 2008 Mar 27 1409 1411
22. E.A. Perez, M.M. Reinholz, D.W. Hillman, and et al. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial J Clin Oncol 28 28 2010 Oct 1 4307 4315
23. S. Ithimakin, K.C. Day, F. Malik, and et al. HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab Cancer Res 73 5 2013 Mar 1 1635 1646
24. N. Duru, M. Fan, D. Candas, and et al. HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells Clin Cancer Res 18 24 2012 Dec 15 6634 6647
25. M. Barok, M. Balazs, P. Nagy, and et al. Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor Cancer Lett 260 1-2 2008 Feb 18 198 208
26. V. Bozionellou, D. Mavroudis, M. Perraki, and et al. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer Clin Cancer Res 10 24 2004 Dec 15 8185 8194
27. V. Georgoulias, V. Bozionelou, S. Agelaki, and et al. Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study Ann Oncol 23 7 2012 Jul 1744 1750
28. S. Park, Z. Jiang, E.D. Mortenson, and et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity Cancer Cell 18 2 2010 Aug 9 160 170
29. D.F. Hayes, T.M. Walker, B. Singh, and et al. Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer Int J Oncol 21 5 2002 Nov 1111 1117
30. H. Joensuu, P.L. Kellokumpu-Lehtinen, P. Bono, and et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer N Engl J Med 354 8 2006 Feb 23 809 820
31. A.G. Tibbe, M.C. Miller, and L.W. Terstappen Statistical considerations for enumeration of circulating tumor cells Cytometry A 71 3 2007 Mar 154 162
32. C.A. Hudis, W.E. Barlow, J.P. Costantino, and et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system J Clin Oncol 25 15 2007 May 20 2127 2132
33. J.B. Smerage, W.E. Barlow, G.N. Hortobagyi, and et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500 J Clin Oncol 32 31 2014 Nov 1 3483 3489
34. C. Bettegowda, M. Sausen, R.J. Leary, and et al. Detection of circulating tumor DNA in early- and late-stage human malignancies Sci Transl Med 224 2014 Feb
35. C. Alix-Panabieres, and K. Pantel Challenges in circulating tumour cell research Nat Rev Cancer 14 9 2014 Sep 623 631
36. I. Garcia-Murillas, G. Schiavon, B. Weigelt, and et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer Sci Transl Med 302 2015 Aug 26
37. E. Olsson, C. Winter, A. George, and et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease Embo Mol Med 8 2015 May 18 47